| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.026 | 0.8 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.031 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.9 |